🚀 VC round data is live in beta, check it out!
Guangzhou Innogen Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Guangzhou Innogen Pharma and similar public comparables like Septerna, ACROBiosystems, Inventiva, GNI Group and more.
Guangzhou Innogen Pharma Overview
About Guangzhou Innogen Pharma
Guangzhou Innogen Pharmaceutical Group Co Ltd is a company in Asia to commercialize an innovative, humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It has commercialized Efsubaglutide Alfa (brand name: Diabegone), its Core Product, for the treatment of type 2 diabetes (T2D) in China. Its core business model is to discover, develop and commercialize innovative therapies for diabetes and other metabolic diseases. The company has built a pipeline of drug candidates targeting diabetes and other metabolic diseases.
Founded
2014
HQ
Employees
96
Website
Sectors
Financials (LTM)
EV
$1B
Guangzhou Innogen Pharma Financials
Guangzhou Innogen Pharma reported last 12-month revenue of $32M and negative EBITDA of ($42M).
In the same LTM period, Guangzhou Innogen Pharma generated $28M in gross profit, ($42M) in EBITDA losses, and had net loss of ($43M).
Revenue (LTM)
Guangzhou Innogen Pharma P&L
In the most recent fiscal year, Guangzhou Innogen Pharma reported revenue of — and EBITDA of ($23M).
Guangzhou Innogen Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $32M | XXX | — | XXX | XXX | XXX |
| Gross Profit | $28M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 88% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($42M) | XXX | ($23M) | XXX | XXX | XXX |
| EBITDA Margin | (129%) | XXX | — | XXX | XXX | XXX |
| EBIT Margin | (133%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($43M) | XXX | ($26M) | XXX | XXX | XXX |
| Net Margin | (133%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Guangzhou Innogen Pharma Stock Performance
Guangzhou Innogen Pharma has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Guangzhou Innogen Pharma's stock price is $2.57.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | 0.0% | XXX | XXX | XXX | $-0.06 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGuangzhou Innogen Pharma Valuation Multiples
Guangzhou Innogen Pharma trades at 31.8x EV/Revenue multiple, and (24.6x) EV/EBITDA.
EV / Revenue (LTM)
Guangzhou Innogen Pharma Financial Valuation Multiples
As of April 20, 2026, Guangzhou Innogen Pharma has market cap of $1B and EV of $1B.
Equity research analysts estimate Guangzhou Innogen Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Guangzhou Innogen Pharma has a P/E ratio of (27.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 31.8x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | (24.6x) | XXX | (44.5x) | XXX | XXX | XXX |
| EV/EBIT | (24.0x) | XXX | (36.8x) | XXX | XXX | XXX |
| EV/Gross Profit | 36.2x | XXX | — | XXX | XXX | XXX |
| P/E | (27.5x) | XXX | (45.9x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (41.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Guangzhou Innogen Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Guangzhou Innogen Pharma Margins & Growth Rates
Guangzhou Innogen Pharma's revenue in the last 12 month grew by 177%.
Guangzhou Innogen Pharma's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.3M for the same period.
Guangzhou Innogen Pharma's rule of 40 is 190% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Guangzhou Innogen Pharma's rule of X is 535% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Guangzhou Innogen Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 177% | XXX | — | XXX | XXX | XXX |
| EBITDA Margin | (129%) | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | (66%) | XXX | 111% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 190% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 535% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 82% | XXX | — | XXX | XXX | XXX |
| G&A Expenses to Revenue | 40% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Guangzhou Innogen Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Guangzhou Innogen Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Septerna | XXX | XXX | XXX | XXX | XXX | XXX |
| ACROBiosystems | XXX | XXX | XXX | XXX | XXX | XXX |
| Inventiva | XXX | XXX | XXX | XXX | XXX | XXX |
| GNI Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Savara | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Guangzhou Innogen Pharma M&A Activity
Guangzhou Innogen Pharma acquired XXX companies to date.
Last acquisition by Guangzhou Innogen Pharma was on XXXXXXXX, XXXXX. Guangzhou Innogen Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Guangzhou Innogen Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGuangzhou Innogen Pharma Investment Activity
Guangzhou Innogen Pharma invested in XXX companies to date.
Guangzhou Innogen Pharma made its latest investment on XXXXXXXX, XXXXX. Guangzhou Innogen Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Guangzhou Innogen Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Guangzhou Innogen Pharma
| When was Guangzhou Innogen Pharma founded? | Guangzhou Innogen Pharma was founded in 2014. |
| Where is Guangzhou Innogen Pharma headquartered? | Guangzhou Innogen Pharma is headquartered in China. |
| How many employees does Guangzhou Innogen Pharma have? | As of today, Guangzhou Innogen Pharma has over 96 employees. |
| Is Guangzhou Innogen Pharma publicly listed? | Yes, Guangzhou Innogen Pharma is a public company listed on HKEX. |
| What is the stock symbol of Guangzhou Innogen Pharma? | Guangzhou Innogen Pharma trades under 02591 ticker. |
| When did Guangzhou Innogen Pharma go public? | Guangzhou Innogen Pharma went public in 2025. |
| Who are competitors of Guangzhou Innogen Pharma? | Guangzhou Innogen Pharma main competitors are Septerna, ACROBiosystems, Inventiva, GNI Group. |
| What is the current market cap of Guangzhou Innogen Pharma? | Guangzhou Innogen Pharma's current market cap is $1B. |
| What is the current revenue of Guangzhou Innogen Pharma? | Guangzhou Innogen Pharma's last 12 months revenue is $32M. |
| What is the current revenue growth of Guangzhou Innogen Pharma? | Guangzhou Innogen Pharma revenue growth (NTM/LTM) is 177%. |
| What is the current EV/Revenue multiple of Guangzhou Innogen Pharma? | Current revenue multiple of Guangzhou Innogen Pharma is 31.8x. |
| Is Guangzhou Innogen Pharma profitable? | No, Guangzhou Innogen Pharma is not profitable. |
| What is the current EBITDA of Guangzhou Innogen Pharma? | Guangzhou Innogen Pharma has negative EBITDA and is not profitable. |
| What is Guangzhou Innogen Pharma's EBITDA margin? | Guangzhou Innogen Pharma's last 12 months EBITDA margin is (129%). |
| What is the current EV/EBITDA multiple of Guangzhou Innogen Pharma? | Current EBITDA multiple of Guangzhou Innogen Pharma is (24.6x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.